🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

Recruitingn/aAges 6 Months - 6 YearsAllChildren's Hospital Medical Center, Cincinnati
NCT07356050 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Participants with confirmed Sickle Cell Disease. 2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines. 3. Willing and able to provide informed consent 4. Ability to comply with study related evaluations and follow-up visits. Exclusion Criteria: 1\. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
💊

What it tests

  • Not listed
📍

Where

3 sites
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Korle Bu Teaching Hospital
Accra, Ghana
Bugando Medical Centre
Mwanza, Tanzania
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy